Is Traws Pharma, Inc. overvalued or undervalued?

As of 12 August 2020, Traws Pharma, Inc. has moved from a grade of risky to does not qualify, indicating a significant deterioration in its valuation outlook. The company is currently considered undervalued, primarily due to its extreme financial ratios, including a P/E ratio of 0, an EV to EBIT of 0.14, and an ROE of 939.05%. These figures suggest that the market is not assigning any value to the company's earnings, which raises concerns about its financial health and future prospects.
In comparison to its peers, Traws Pharma's valuation metrics are starkly lower; for instance, Catalyst Biosciences, Inc. has a P/E ratio of 90.0214, highlighting how Traws Pharma is lagging behind in market perception. Other peers like Microbot Medical, Inc. also reflect a negative EV to EBITDA ratio of -4.7346, indicating that Traws Pharma is not alone in its struggles, but its current valuation remains particularly concerning. Additionally, the company's stock has significantly underperformed against the S&P 500, with a year-to-date return of -82.55% compared to the index's 2.44%, further underscoring its undervaluation in the market.